Early antibody responses associated with survival in COVID19 patients

Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate C...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PLoS pathogens 2021-07, Vol.17 (7), p.e1009766-e1009766
Hauptverfasser:	Zhou, Zhao-Hua, Dharmarajan, Sai, Lehtimaki, Mari, Kirshner, Susan L, Kozlowski, Steven
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antigen-antibody reactions Antigens Biology and Life Sciences Care and treatment Clinical trials Coronaviruses COVID-19 Disease transmission Hospital patients Hospitalization Immunoassay Immunological research Medicine and Health Sciences Monoclonal antibodies Mortality Patient outcomes Patients Prediction models Proteins Research and Analysis Methods Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Spike protein Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!